Impact Factor:1.137 | Ranking:21/36 in Social Sciences, Biomedical | 81/136 in Public, Environmental & Occupational Health | 5-Year Impact Factor:1.396Source:2012 Journal Citation Reports® (Thomson Reuters, 2013)
David C Giles David.Giles{at}winchester.ac.uk University of Winchester, UKThis article considers the fate of Asperger’s disorder in the light of proposals for the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) to collapse Asperger’s disorder along with other pervasive developmental disorders into a general spectrum of autism. It is argued that a powerful lay and scientific culture has evolved around the concept of Asperger’s disorder, which has found a particularly compelling voice over the last decade in the online Asperger community, with websites such as Wrong Planet recruiting tens of thousands of members. In order to assess the impact of these proposed changes on the online Asperger community, 19 threads on the topic of Diagnostic and Statistical Manual of Mental Disorders (5th ed.) are analysed according to the arguments that community members put forward in favour of, or in opposition to, the proposals. Many members embrace the notion of the spectrum and have already coined a new identity – ‘spectrumite’ – to adapt to the diagnostic shift. Others, however, are suspicious of the motives behind the absorption of Asperger’s disorder, and potential threats to the provision of services as well as the strong ‘aspie’ identity that reflects the large literature and the online public sphere around Asperger’s disorder. To what extent this culture poses a challenge to the authority of the Diagnostic and Statistical Manual of Mental Disorders is uncertain at present. © 2013 SAGE Publications. Los Angeles, London, New Delhi, Singapore and Washington DC
Showing posts with label Changes. Show all posts
Showing posts with label Changes. Show all posts
Wednesday, November 13, 2013
Thursday, October 24, 2013
Changes to Cancer Research UK research funding policies
Cancer Research UK has made some amendments to its research funding policies. A brief outline of policies affected is as follows:
Open Access and UKPMC: purpose and scope of the policy has been further defined;instructions on acknowledging Cancer Research UK funding has been refined;methods of ensuring availability of publications has been expanded and clarified;changes are effective from 1 March 2011.Applications from Post-retirement scientists: policy has been retired in conjunction with recent government legislation on default retirement age;retirement of this policy is effective 6 April 2011.Payment of Consultant Clinician Salaries This new policy has been written to clarify our current working practice and is relevant in any situation where Cancer Research UK pays part or all of the salary of a Consultant Clinician through a research grant.See Terms and Conditions & Policies for further details of these changes.
Changes to our bursary schemes
Cancer Research UK regularly reviews the funding schemes we offer. We have made some changes to our bursary schemes and funding for short-term training opportunities.
From 1st October 2010, we will no longer provide support for Masters or Diploma courses, or for workshops or training courses.
We will shortly be making changes to our Collaborator Bursary scheme, so please keep an eye on the website for more details of the new scheme.
Our Research Bursaries for clinicians and professions allied to medicine are unchanged. The next deadline for the Research Bursaries is 11th January 2011.
Changes to our funding committees and schemes
Cancer Research UK is making changes to the structure of its funding committees and funding schemes. Feedback from the cancer research community has been broadly consistent - the current funding structures arbitrarily and unhelpfully fragment our response-mode funding of biological and translational research activity.
Increasingly, we are seeing applications to the Biological Sciences Committee which have a strong translational component, and applications to the Clinical and Translational Research Committee that have a significant basic science element.
We are also receiving ever-increasing numbers of high-quality applications and it is likely that we will not be able to fund all those that reach the quality benchmark. We need to make our funding decisions based on quality and on strategic priority. A more joined up view of the science at any one time will enable us to do so more effectively, while still maintaining the excellence of the science as the predominant driver.
Cancer Research UK has had one funding committee covering basic research - the Biological Sciences Committee - and a further three, the Clinical and Translational Research Committee, Discovery Committee and the Biomarkers & Imaging Discovery & Development Committee, covering translational research.
These four funding committees will shortly be replaced by a new Science Committee. The new committee considers programme grant applications in any area of basic and translational research. Project grant applications are only considered in the specific areas of Biomarker research and Drug Discovery. Because there will only be a single committee, you will have the opportunity to submit applications that are broader in scope than through our current funding streams.
The committee will be asked to not only consider firstly the scientific quality of the projects and programmes submitted to Cancer Research UK, but also their relevance to our research strategy. The committee will make a funding decision based on both of these factors.
Other funding streams will remain unchanged. The Population Research Committee (PRC), Clinical Trials Awards and Advisory Committee (CTAAC) and the New Agents Committee (NAC) will continue to fund along existing lines.
We will also be maintaining our current range of fellowships and funding for new investigators in the form of our Career Development Fellowships, Senior Cancer Research Fellowships, Career Establishment Awards and Clinician Scientist Fellowships. We will continue to fund graduate training for PhD students and clinical fellows through our Centre Training Accounts.
In parallel to the changes in the funding committee structure, we have also reorganised our internal research funding teams. Some of your current contacts in the Cancer Research UK office will have changed, so please do check the website to find out who to talk to about your current grant or new application.
As well as making changes to the operations of the grant schemes, we have merged the teams looking after the Cancer Centres and the Experimental Cancer Medicine Centres. There are lots of links between these two areas of our work, and the new team will help deliver our objectives, and those of our partners, for these two important networks.
These changes will ensure that we continue to fund the best quality research and this is accomplished in the most efficient way. If you have any queries about the new structures, please contact Dr Jamie Meredith: jamie.meredith@cancer.org.uk
We are currently in the process of finalising deadlines for the new funding schemes offered by the Science Committee. These will be publicised on our website shortly.
Deadlines for schemes offered by our PRC, CTAAC, NAC and Fellowship Committees will not change with this new restructure.
Subscribe to:
Posts (Atom)